Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | P4HB | P07237 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 7/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 5/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7710176 | 0.81 | HNF4A (0.42) | KDM4ELMNAHSD17B10P4HBESR1 | |
| SCHEMBL910546 | 0.78 | APP (0.43) | KDM4ELMNAHSD17B10CA6CA9 | |
| SCHEMBL97003 | 0.78 | GRM5 (0.46) | — | |
| SCHEMBL200168 | 0.77 | P4HB (0.51) | P4HBESR1ESR2CA3CA6 | |
| SCHEMBL14307269 | 0.77 | ESR1 (0.44) | KDM4ELMNAHSD17B10P4HBESR1 | |
| SCHEMBL29826346 | 0.77 | P4HB (0.51) | P4HBESR1ESR2CA3CA6 | |
| SCHEMBL2552386 | 0.73 | SLC2A1 (0.35) | — | |
| SCHEMBL7152669 | 0.73 | GAA (0.47) | KDM4ELMNAHSD17B10CA9 | |
| SCHEMBL7160560 | 0.73 | HSD17B10 (0.50) | LMNAHSD17B10ESR1ESR2HSD17B1 | |
| SCHEMBL1044275 | 0.73 | HDAC1 (0.41) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | AXYS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | claimed |
| US-6492362-B1 | Compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | claimed |
| WO-2001019808-A1 | CHEMICAL COMPOUNDS AND COMPOSITIONS AND THEIR USE AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| US-20190071407-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2019-03-07 | — | — | US | disclosed |
| EP-2536698-B1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| WO-2001019808-A1 | CHEMICAL COMPOUNDS AND COMPOSITIONS AND THEIR USE AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071407-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDES | ACHE, CHRM1, ITPR3 | KDM4E 3040/4885LMNA 1648/4885HSD17B10 3011/4885 |
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | CTSS, CTSB, CTSE | KDM4E 4465/4885LMNA 1476/4885HSD17B10 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.